ATE429918T1 - Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung - Google Patents

Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung

Info

Publication number
ATE429918T1
ATE429918T1 AT02755241T AT02755241T ATE429918T1 AT E429918 T1 ATE429918 T1 AT E429918T1 AT 02755241 T AT02755241 T AT 02755241T AT 02755241 T AT02755241 T AT 02755241T AT E429918 T1 ATE429918 T1 AT E429918T1
Authority
AT
Austria
Prior art keywords
oxazin
thieno
inhibiting effect
lipase inhibiting
lipase
Prior art date
Application number
AT02755241T
Other languages
English (en)
Inventor
Harold Francis Hodson
Christopher R Dunk
Richard M J Palmer
Dale Robert Mitchell
Veronique Birault
Russell George Hunt
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121019A external-priority patent/GB0121019D0/en
Priority claimed from GB0206031A external-priority patent/GB0206031D0/en
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Application granted granted Critical
Publication of ATE429918T1 publication Critical patent/ATE429918T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02755241T 2001-08-30 2002-08-23 Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung ATE429918T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121019A GB0121019D0 (en) 2001-08-30 2001-08-30 /nhibitors
GB0206031A GB0206031D0 (en) 2002-03-14 2002-03-14 Inhibitors
PCT/GB2002/003903 WO2003020282A1 (en) 2001-08-30 2002-08-23 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity

Publications (1)

Publication Number Publication Date
ATE429918T1 true ATE429918T1 (de) 2009-05-15

Family

ID=26246489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02755241T ATE429918T1 (de) 2001-08-30 2002-08-23 Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung

Country Status (19)

Country Link
US (2) US7407954B2 (de)
EP (1) EP1446125B1 (de)
JP (2) JP2005527469A (de)
KR (1) KR100934256B1 (de)
CN (1) CN1556706B (de)
AR (1) AR036399A1 (de)
AT (1) ATE429918T1 (de)
AU (1) AU2002321536B2 (de)
CA (1) CA2458213A1 (de)
DE (1) DE60232170D1 (de)
HU (1) HUP0401298A3 (de)
MX (1) MXPA04001922A (de)
MY (1) MY139608A (de)
NO (1) NO20041295L (de)
NZ (1) NZ531272A (de)
PL (1) PL368994A1 (de)
RU (1) RU2324696C2 (de)
WO (1) WO2003020282A1 (de)
ZA (1) ZA200401595B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0401298A3 (en) * 2001-08-30 2008-03-28 Alizyme Therapeutics Ltd Thieno [1,3] oxazin-4-ones with lipase inhibiting activity, process for their preparation and pharmaceutical compositions containing them
CA2471098A1 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pancreatic lipase inhibitor compounds, their synthesis and use
JP2008517061A (ja) * 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
SU1302659A1 (ru) * 1985-07-09 1991-06-07 Пермский фармацевтический институт 2-(П-Толиламинометиленамино)-6-п-толил-1,3-оксазин-4-он, про вл ющий противовоспалительную активность
DE3540377A1 (de) 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
IL125947A0 (en) 1997-09-17 1999-04-11 American Cyanamid Co 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
EP0985670A1 (de) 1998-08-13 2000-03-15 American Cyanamid Company 1-(3-Heterocyclylphenyl)isothioharnstoff-, -isoharnstoff-, -guanidin- und amidinverbindungen als Herbizide
AU1375000A (en) 1998-11-26 2000-06-13 Novo Nordisk A/S Heterocyclic compounds regulating clotting
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
PE20010588A1 (es) * 1999-09-10 2001-06-23 Procter & Gamble Conjugados polimericos inhibidores de enzimas proteoliticas y lipoliticas
GB0001572D0 (en) * 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
JP2002105081A (ja) * 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
HUP0401298A3 (en) * 2001-08-30 2008-03-28 Alizyme Therapeutics Ltd Thieno [1,3] oxazin-4-ones with lipase inhibiting activity, process for their preparation and pharmaceutical compositions containing them
CA2471098A1 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pancreatic lipase inhibitor compounds, their synthesis and use

Also Published As

Publication number Publication date
NO20041295L (no) 2004-03-29
JP2010159260A (ja) 2010-07-22
EP1446125A1 (de) 2004-08-18
MY139608A (en) 2009-10-30
HUP0401298A3 (en) 2008-03-28
AU2002321536B2 (en) 2007-05-17
HK1064940A1 (en) 2005-02-08
US20090029978A1 (en) 2009-01-29
AR036399A1 (es) 2004-09-08
RU2324696C2 (ru) 2008-05-20
RU2004109588A (ru) 2005-05-10
CN1556706B (zh) 2011-04-27
KR20040052216A (ko) 2004-06-22
MXPA04001922A (es) 2005-03-07
WO2003020282A1 (en) 2003-03-13
ZA200401595B (en) 2005-05-25
US20050075336A1 (en) 2005-04-07
CA2458213A1 (en) 2003-03-13
JP2005527469A (ja) 2005-09-15
DE60232170D1 (de) 2009-06-10
PL368994A1 (en) 2005-04-04
CN1556706A (zh) 2004-12-22
NZ531272A (en) 2006-01-27
US7407954B2 (en) 2008-08-05
HUP0401298A2 (hu) 2004-10-28
EP1446125B1 (de) 2009-04-29
KR100934256B1 (ko) 2009-12-28

Similar Documents

Publication Publication Date Title
DE60202270D1 (de) 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung
DE602004029705D1 (de) 5,7-diaminopyrazoloä4,3-düpyrimidine mit pde-5-hemmender wirkung
CY2014041I1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
ATE279413T1 (de) Pyrazolobenzodiazepine mit cdk2 hemmender wirkung
BR0216099B1 (pt) "conjunto de desgaste".
NO20040654L (no) Gassmikrosfaere-liposomkompositter.
EP1426370A4 (de) Propanolaminderivat mit 1,4-benzodioxanring
ATE519761T1 (de) 5-aminoalkyl-pyrazoloä4,3-düpyrimidine mit phosphodiesterase v inhibierender wirkung
NO20040387L (no) Nedihullsfrigjoringskopling.
ATE429918T1 (de) Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung
ITTO20020744A1 (it) Composizione.
NO20034295L (no) Planteoppkvikker
ES1048400Y (es) Bota-patin mejorada.
BR0103827B1 (pt) cola - pds.
ES1050491Y (es) Chupete infantil.
BR8101236Y1 (pt) desensiladeira.
NL1017571A1 (nl) Plantpot.
FI20011124A0 (fi) Katukivisarja
ITTO20020746A1 (it) Composizione.
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
ITBO20010127A0 (it) Magazzino
FI20011118A0 (fi) Katukivisarja
ES1049298Y (es) Embalaje-expositor.
ES1048703Y (es) Conversor.
ES1048140Y (es) Calcetin-zapato.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties